Corona Immunitas: a nationwide program of antibody studies of SARS-CoV-2 in the Swiss population

Conditions

SARS-CoV2 infection (COVID-19) Infections and Infestations

Tala Ballouz, Dominik Menges, A Anagnostopoulos, Anja Domenghino, Hélène E. Aschmann et al. (8 authors)

BMJ2023-05-31176 citations

10.1136/bmj-2022-074425

Association of plasma zinc levels with anti-SARS-CoV-2 IgG and IgA seropositivity in the general population: A case-control study.

Equey A, Berger MM, Gonseth-Nusslé S, Augsburger M, Rezzi S, Hodgson ACC, Estoppey S, Pantaleo G, Pellaton C, Perrais M, Lenglet S, Rousson V, D'Acremont V, Bochud M.

2023-04-182 citations

10.1016/j.clnu.2023.04.007

Is living in a household with children associated with SARS-CoV-2 seropositivity in adults? Results from the Swiss national seroprevalence study Corona Immunitas.

Blankenberger J, Kaufmann M, Albanese E, Amati R, Anker D, Camerini AL, Chocano-Bedoya P, Cullati S, Cusini A, Fehr J, Harju E, Kohler P, Kriemler S, Michel G, Rodondi N, Rodondi PY, Speierer A, Tancredi S, Puhan MA, Kahlert CR, Corona Immunitas Research Group.

2022-06-206 citations

10.1186/s12916-022-02431-z

Seroprevalence of SARS-CoV-2 antibodies, associated factors, experiences and attitudes of nursing home and home healthcare employees in Switzerland.

West EA, Kotoun OJ, Schori LJ, Kopp J, Kaufmann M, Rasi M, Fehr J, Puhan MA, Frei A, Corona Immunitas Research Group.

2022-03-1611 citations

10.1186/s12879-022-07222-8

High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional study

Philip Bruggmann, Oliver Senn, Anja Frei, Milo A. Puhan, Jan Fehr et al. (6 authors)

Swiss Medical Weekly2022-01-128 citations

10.4414/smw.2022.w30122

Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland

Agnė Ulytė, Thomas Radtke, Irène A. Abela, Sarah R. Haile, Jacob Blankenberger et al. (16 authors)

BMJ Open2021-07-0126 citations

10.1136/bmjopen-2020-047483

Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland

Erin West, Daniela Anker, Rebecca Amati, Aude Richard, Ania Wisniak et al. (33 authors)

International Journal of Public Health2020-10-2499 citations

10.1007/s00038-020-01494-0

Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland

Erin West, Daniela Anker, Rebecca Amati, Aude Richard, Ania Wisniak et al. (33 authors)

Zenodo (CERN European Organization for Nuclear Research)2020-10-24

10.5281/zenodo.4194329

Interventions

Potential participants are either randomly selected from the general population or selected from specific sub-population settings. The process of enrollment is organized by each study center and for e

Eligibility

Inclusion criteria

Inclusion criteria: 1. No acute SARS-CoV-2 infection: no presence of symptoms for at least 48 hours 2. In case of a SARS-CoV-2 infection verified by a RT-PCR test, the earliest inclusion is 21 days after the test date

Exclusion criteria

Exclusion criteria: 1. No informed consent 2. Suspicion of acute COVID-19 infection

Design outcomes

Primary

Measure	Time frame
Seroprevalence of SARS-CoV-2 antibodies measured using peripheral blood sample by venipuncture in the general population and in specific subpopulations at repeated time points during the epidemic in Switzerland	—

Secondary

Measure	Time frame
1. Presence of symptoms suggestive of a common cold, influenza and similar upper respiratory tract infections prior to the first study visit. Measured by baseline questionnaire (at baseline) 2. Potential risk factors and preventive measures for SARS-CoV-2 infection (exposure, socio-economic factors, adherence to general hygiene and physical distancing rules, utilization of mask and gloves). Measured by baseline questionnaire (at baseline) 3. Incidence of self-reported symptoms and SARS-CoV-2 infections after the first study visit in initially seropositive individuals (extent and duration of immunity after infection with SARS-CoV-2). Measured by digital follow-up questionnaire (weekly) 4. Proportion of seronegative individuals of the first investigation wave who will self-report symptoms and infection with SARS-CoV-2. Measured by digital follow-up questionnaire (weekly) 5. Course over time in access to health care, health care renunciation, going outside (frequency, reason, physical activity), preventive measures with respect to COVID-19. Measured by digital follow-up questionnaire (weekly and monthly) 6. Course over time in mental well-being, specifically stress, anxiety and depression. Measured by digital follow-up questionnaire (monthly)	—

Measure

Time frame

1. Presence of symptoms suggestive of a common cold, influenza and similar upper respiratory tract infections prior to the first study visit. Measured by baseline questionnaire (at baseline) 2. Potential risk factors and preventive measures for SARS-CoV-2 infection (exposure, socio-economic factors, adherence to general hygiene and physical distancing rules, utilization of mask and gloves). Measured by baseline questionnaire (at baseline) 3. Incidence of self-reported symptoms and SARS-CoV-2 infections after the first study visit in initially seropositive individuals (extent and duration of immunity after infection with SARS-CoV-2). Measured by digital follow-up questionnaire (weekly) 4. Proportion of seronegative individuals of the first investigation wave who will self-report symptoms and infection with SARS-CoV-2. Measured by digital follow-up questionnaire (weekly) 5. Course over time in access to health care, health care renunciation, going outside (frequency, reason, physical activity), preventive measures with respect to COVID-19. Measured by digital follow-up questionnaire (weekly and monthly) 6. Course over time in mental well-being, specifically stress, anxiety and depression. Measured by digital follow-up questionnaire (monthly)

—

Countries

Switzerland

Contacts

Public ContactJan Fehr

jan.fehr@uzh.ch+41 44 634 46 79

Outcome results

None listed